and should make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser.
Cautionary note regarding forward-looking statements: This Document contains statements about ReNeuron Group plc that are or may be ''forward-looking statements''. All statements, other than statements of historical facts, included in this Document may be forward-looking statements and are subject to, inter alia, known and unknown risks, uncertainties and other factors. Without limitation, any statements preceded or followed by, or that include, the words ''targets'', ''plans'', ''believes'', ''expects'', ''aims'', ''intends'', ''will'', ''may'', ''should'', ''anticipates'', ''estimates'', ''projects'', ''would'', ''could'', ''continue'' or words or terms of similar substance or the negative thereof, are forward-looking statements. Forward-looking statements include statements relating to the following: managements' strategic vision, aims and objectives; the conduct of clinical trials; the filing dates for product licence applications; the Company's ability to find partners for the development and commercialisation of its products; the effect of competition; trends in results of operations; margins; the overall pharmaceutical market; and exchange rates. These forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of ReNeuron Group plc. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person, or industry results, to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate in the future. Investors should not place undue reliance on such forward-looking statements and, save as is required by law or regulation (including to meet the requirements of the AIM Rules and the Disclosure and Transparency Rules), ReNeuron Group plc does not undertake any obligation to update publicly or revise any forward-looking statements (including to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based). All subsequent oral or written forward-looking statements attributed to ReNeuron Group plc or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements contained in this Document are based on information available to the Directors of ReNeuron Group plc at the date of this Document, unless some other time is specified in relation to them, and the posting or receipt of this Document shall not give rise to any implication that there has been no change in the facts set forth herein since such date. (1) References to times in this Document are to London time (unless otherwise stated).
(2) The dates and timing of the events in the above timetable and in the rest of this Document are indicative only and may be subject to change. (3) If any of the above times or dates should change, the revised times and/or dates will be notified by an announcement through an RNS. 
PLACING STATISTICS
Scientific Officer) John Berriman, (Non-Executive Director) Simon Cartmell, (Non-Executive Director) Mark Docherty, (Non-Executive Director) Dr. Paul Harper, (Non-Executive Director) Dr. Tim Corn, (Non-Executive Director)
2.
ReNeuron ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered ''off-the-shelf'' to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications -its ReNcell The Company has today separately announced the preliminary unaudited financial statements of the Group for the year ended 31 March 2013 and provided in such announcement an update regarding the its therapeutic programmes and other activities. A copy of this announcement is available from the Company's website www.reneuron.com.
The Company has made considerable progress on its therapeutic programmes. The Phase I clinical trial of the Company's stem cell therapy candidate for stroke has yielded encouraging data and a Phase II study is planned to commence shortly, as is a Phase I study with the Company's therapeutic candidate for critical limb ischaemia. The Company expects its stem cell therapy candidate for the blindnesscausing disease, retinitis pigmentosa, to enter the clinic next year.
In addition, the Company has been awarded a non-dilutive grant package totalling £7.8 million from the Welsh Government to establish a cell manufacturing and development laboratory facility in South Wales over the next two years, for late stage clinical and commercial product requirements. The Company will move its principal operations to this facility as it is phased in over this period.
The Company is pleased to announce that renowned Welsh life sciences entrepreneur, Sir Chris Evans, will be appointed upon closing of the Placing as a non-executive director of the Company.
3.
Reasons for the Fundraising Subject to the completion of the Placing in respect of all Placing Shares, the net proceeds of the Placing together with the Welsh grant package and the Company's existing cash resources will, in the opinion of the Directors, provide the Company with sufficient working capital to fund all of its core therapeutic programmes through Phase II studies and to consequent value inflection through commercial development deals or a broader strategic transaction. It will also enable the Company to secure manufacturing capability, and margin, as its therapeutic candidates move closer to market.
4.
Details of the Placing and the Placing Agreement It was announced today that the Company has conditionally placed 1,014,000,000 new Ordinary Shares at 2.5 pence per share with existing and new investors and the Directors to raise approximately £25.35 million before expenses.
To enable certain Placees to take advantage of VCT/EIS tax treatment, the Placing will comprise two Admissions.
The Placing Shares will, when issued, rank in full for all dividends declared, made or paid after the date of their Admission and otherwise pari passu with the then existing Ordinary Shares.
In connection with the Placing, the Company and Cenkos have entered into the Placing Agreement pursuant to which and conditional upon, inter alia, Admission of the First Placing Shares taking place on or before 8 August 2013 (or such later time and date as the Company and Cenkos may agree, being no later than 22 August 2013) Cenkos has agreed to use its reasonable endeavours to procure subscribers for the Placing Shares at the Issue Price. The Placing is not underwritten.
Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM. Assuming that the Resolutions are passed, it is expected that the Admissions will become effective and dealings in the Placing Shares will commence as follows: The Placing Agreement contains customary warranties and an indemnity from the Company in favour of Cenkos together with provisions which enable Cenkos to terminate the Placing Agreement in certain circumstances prior to Admission (as applicable), including where any warranties are found to be untrue, inaccurate or misleading in a material respect and also in the event of a material adverse change in the financial position or prospects of the Group or in national or international financial, market, economic or political conditions.
Under the Placing Agreement the Company has agreed to pay Cenkos a commission on the value of certain new Ordinary Shares issued as part of the Placing and a fixed fee. The Company has also agreed to pay all other costs, charges and expenses incidental to the Placing and Admissions.
5.
Effect of the Placing Upon completion of the Second Admission, the Enlarged Share Capital is expected to be 1,788,827,700 Ordinary Shares. On this basis, the Placing Shares will represent approximately 57 per cent. of the Enlarged Share Capital.
The Placing Shares will, when issued and fully paid, rank pari passu in all respects with the then existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of their Admission.
6.
Resolutions The Resolutions to be proposed at the General Meeting are, in summary, as follows:
(1) an ordinary resolution, to grant the Directors authority to allot the Placing Shares; and 9 c108248pu010Proof6:20.7.13_02:16B/LRevision:0OperatorAllS (2) a special resolution, to disapply pre-emption rights granted under the Act, in respect of the allotment of the Placing Shares.
The authorities set out in Resolutions 1 and 2 are in addition to the Existing Authorities conferred on the Directors by Shareholders at the 2012 AGM. 
General Meeting and action to be taken

8.
Financial Information The most recently published audited accounts of the Group are for the twelve month period ending on 31 March 2012 (the ''last accounts'') and the most recently published unaudited preliminary statements of the Group are for the twelve month period ending on 31 March 2013 (the ''last prelims''). Electronic copies of the last accounts and last prelims are available from the Company's website www.reneuron.com.
9.
Intentions of the Directors in relation to the Placing The Directors have agreed to subscribe for Placing Shares as follows: 
Recommendation
The Directors consider the Placing to be in the best interests of the Company and the Shareholders as a whole and, accordingly, unanimously recommend that you vote in favour of the Resolutions to be proposed at the General Meeting as they intend to do in respect or their own holdings of Ordinary Shares.
Copies of this Document will be available for inspection free of charge at the registered office of the Company during normal business hours on any Business Day from the date of this Document up to and including the date of Second Admission.
Appointment of Non-Executive Director
The In this Notice words and defined terms shall have the same meanings as words and defined terms in the Document to which this Notice is attached.
ORDINARY RESOLUTION 1.
THAT, the Directors be and are hereby generally and unconditionally authorised pursuant to section 551 of the Act (in addititon to all existing authorities conferred upon the Directors pursuant to section 551 of the Act), to exercise all the powers of the Company to allot shares in the capital of the Company and to grant rights to subscribe for or convert any security into such shares (all of which transactions are hereafter referred to as an allotment of ''Relevant Securities'') representing up to £10,140,000 in nominal value in aggregate of shares in connection with the Placing, provided that such authority shall expire (unless previously renewed, varied or revoked by the Company in general meeting) 15 months after the date of the passing of this Resolution or at the conclusion of the next annual general meeting of the Company, whichever occurs first, save that the Company may before such expiry, revocation or variation make an offer or agreement which would or might require relevant securities to be allotted after such expiry, revocation or variation and the Directors may allot relevant securities in pursuance of such offer or agreement as if the authority hereby conferred had not expired or been revoked or varied.
SPECIAL RESOLUTION
2.
THAT, subject to and conditional upon the passing of Resolution 1 above, (and in addition to all existing unexercised powers of the Directors under section 570 of the Act) the Directors be and are hereby empowered pursuant to section 570 of the Act to allot equity securities (as defined by section 560 of the Act) for cash pursuant to the authority conferred by Resolution 1 up to an aggregate nominal amount of £10,140,000 in connection with the Placing as if section 561 of the Act did not apply to any such allotment provided that such powers shall expire (unless previously renewed, varied or revoked by the Company in general meeting) 15 months after the date of the passing of this Resolution or at the conclusion of the next annual general meeting of the Company, whichever occurs first, save that the Company may before such expiry, revocation or variation make an offer or agreement which would or might require equity securities to be allotted after such expiry, revocation or variation and the Directors may allot equity securities in pursuance of such offer or agreement as if such power hereby conferred had not expired or been revoked or varied.
BY ORDER OF THE BOARD Patrick Huggins Company Secretary
Dated: 22 July 2013
Registered office: 10 Nugent Road Surrey Research Park Guildford Surrey GU2 7AF Notes (1) A Shareholder entitled to attend and vote at the General Meeting is also entitled to appoint one or more proxies to attend, speak and vote on a show of hands and on a poll instead of him or her. The proxy need not be a Shareholder of the Company. Where a Shareholder appoints more than one proxy, each proxy must be appointed in respect of different shares comprised in his shareholding which must be identified on the Form of Proxy. If you fail to do so, the appointment will be rejected as invalid. You must also tick the box on each Form of Proxy to indicate it is one or more than one appointment in respect of your shareholding. Each proxy
